Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating non-clinical proof of concept for SolidT cells co-administered with therapeutic antibodies.
Cambridge, MA, USA – WEBWIRE – Tuesday, April 9, 2024
Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the presentation of pre-clinical data at the annual meeting of the American Association for Cancer Research demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed, and establish immune memory to eliminate secondary tumors.
The presentation is entitled A modified FcγRI expressing T cell (SolidT) exhibits profound anti-tumor activity followed by maturation into effector memory t cells that can be reactivated to kill a secondary tumor. It will be presented as part of the Adoptive Cell Therapies 4 Session, Poster Section 1, between 1:30 and 5:00 PT on Tuesday, April 9.
Until now, treatment of solid tumors with autologous T-cell therapies, such as CAR-T, have been limited by T-cell exhaustion, toxicity, and immunosuppressive tumor microenvironments. Furthermore, each solid tumor target requires a unique CAR-T cell product. Gilboas SolidT technology overcomes these limitations by utilizing a novel, engineered antibody receptor whereby the SolidT cells are activated specifically against high antigen expressing tumor cells, while sparing normal cells with low expression of the same antigens. The SolidT cells are engineered to target tumor cells via coadministration with therapeutic monoclonal antibodies. This activation mechanism prevents premature exhaustion, while also reducing the risk of systemic cytokine-related toxicities. It also allows for a single manufacturing process to generate SolidT cells to be used across multiple tumor types.
The abstract can be viewed here.
About Gilboa Therapeutics
Gilboa Therapeutics is a preclinical-stage biopharmaceutical company that is focused on the development of novel and high-impact, next-generation cancer immunotherapies designed to harness the power of patients own immune systems to treat cancer, improve outcomes and save lives. Backed by NFX, companys SolidT technology leverages T-cells that are genetically engineered to target tumor cells while leaving healthy tissue unharmed. Learn more at www.gilboa.bio.
WebWireID320320
Contact Information
Barry Labinger
CEO
Gilboa Therapeutics
barry.labinger@gilboatx.com
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT’s cutting-edge technologies into the market.
Dr Tulip brings decades of invaluable experience in developing and successfully commercializing imaging agents to MVT. With a notable track record of contributing to the regulatory approval of 15 new chemical entities and expanding indications, Dr Tulip’s expertise aligns seamlessly with MVT’s mission to bring the revolutionary imaging agent, MVT-100, to market. His deep industry knowledge and extensive network are poised to be a catalyst for MVT’s next phase of growth.
“We are thrilled to welcome Thom Tulip to the team. Having collaborated during his tenure at DuPont, Thom will play a vital role in propelling MVT-100 from the late clinical stage to NDA,” said Dr. Evan Unger, Founder, and Chairman of the board. “Dr. Tulip has been with us for just a month, and his insights have already strengthened our strategy, and his robust industry connections will undoubtedly accelerate MVT’s success. The team is hugely strengthened with his joining the Company,” added Dr. Emmanuelle Meuillet, Chief Operating and Scientific Officer.
As MVT rapidly transitions from a research organization to a clinical-stage biopharma, Dr Tulip’s extensive experience and expertise in this domain will be instrumental in ensuring a seamless and successful transition.
For more information about Microvascular Therapeutics and its new CBO, please contact: Company Contact: Microvascular Therapeutics Dr. Evan C. Unger, Chairman BOD Dr. Emmanuelle Meuillet, COO/CSO
About Microvascular Therapeutics (MVT): Microvascular Therapeutics is a clinical-stage biotechnology company based in Tucson, Arizona, leading in microbubble and nanobubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound, advancing the field for the diagnosis and treatment of diseases, including vascular diseases. MVT has pioneered a new, patented microbubble serving as a platform for developing agents for molecular imaging and image-guided therapy. Learn more at [www.mvtpharma.com](http://www.mvtpharma.com).
MELBOURNE, Jan 16, 2024 – (ACN Newswire) – Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company’s PRT120 oral therapy for peanut allergy.
“SPRIM brings valuable expertise, capabilities and an international investment network to Prota’s technology and clinical program,” said Prota Executive Chairman Kelly Constable. “This partnership and funding will accelerate Prota’s drug development plans and clinical trial program, and we look forward to this strategic collaboration as Prota moves toward its Phase 3 trial.”
“Closing financing in the current market validates the potential of Professor Mimi Tang’s technology to deliver meaningful outcomes for patients with peanut allergy, where there is a persistent unmet need,” said Dr. Paul Kelly, founding partner and director, OneVentures, one of Australia’s leading Venture Capital firms with more than AU$800 million under management. “Prota’s treatment offers the promise of an induction of remission of allergy, allowing patients to eat peanuts freely and enjoy an improved quality of life.”
The new investment will advance the chemistry, manufacturing, and controls (CMC), accelerate the path to an Investigational New Drug Application (IND), and expand Prota’s executive management team to bring on board critical expertise in late-stage drug development and commercialization.
The peanut allergy therapeutics market is projected to reach US$1 billion by 2030, growing at a compound annual rate of 10%, in part due to the increasing incidence of peanut allergy globally. In the US, peanut allergy is the most prevalent food allergy in children, affecting 2.5% of children. The most significant impact of food allergy on both patients and their families is a reduced quality-of-life and psychological distress, caused by the lifestyle and dietary restrictions of allergen avoidance and the unpredictability of reactions to accidental exposures.
Prota’s technology is based on over 15 years of research led by Professor Mimi Tang at the Murdoch Children’s Research Institute (MCRI).
“Our Phase 2b[1] multicenter randomized controlled trial conducted by MCRI showed that PRT120 is highly effective at inducing remission of allergy, and more importantly, leads to significant and clinically meaningful improvement in quality of life, compared with standard care (placebo treatment),” said Prota founder Professor Tang. “Long-term follow-up data further shows that children in remission have fewer reactions, less rescue epinephrine use, and far greater improvement in quality of life than children who are only desensitized, validating remission as the patient-preferred outcome.”
“The food immunotherapy market is expanding rapidly with a range of therapies currently in early- through late-stage development. We are excited to support Prota in its journey to deliver a solution that can potentially transform the treatment of peanut allergy by releasing patients from the shackles of life-long maintenance dosing and allergen avoidance,” said Michael Shleifer, managing partner and co-founder of SGI, a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries.
About SPRIM Global Investments (SGI)
SPRIM Global Investments (SGI) is a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries. SGI invests in biotechnology, digital health and R&D service companies to commercialize the newest technologies and accelerate innovations that are the future of health around the world. For more information, visit: www.sprim.net.
About Prota Therapeutics
Prota Therapeutics is an Australian proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments for food allergy. Prota holds intellectual property covering the proprietary food immunotherapy technology developed at the MCRI. The company is, in part, a OneVentures’ Healthcare Fund III investment. This fund was established with investment in part from the Australian Commonwealth Government through the BioMedical Translation Fund initiative. Prota Therapeutics has its headquarters in Melbourne, Australia. For more information please visit: https://protatherapeutics.com/.
HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.
Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company’s robust pipeline. HighTide’s lead candidate HTD1801, is a novel multifunctional molecule, being developed for the treatment of patients suffering from complex metabolic and digestive diseases.
HighTide has successfully completed multiple clinical trials of HTD1801 and continues to advance its global development programs as follows:
— A Phase 2 clinical study in type 2 diabetes (T2DM) is near completion; — A Phase 2b clinical study in nonalcoholic steatohepatitis (NASH) has been initiated; and — A successful End-of-Phase 2 (EOP2) meeting was held with the U.S. Food and Drug Administration (FDA) based on the positive findings from the Phase 2 clinical study in primary sclerosing cholangitis (PSC).
“After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round. We are grateful that our investors have such strong confidence in HighTide’s team, the commercial value of our pipeline, and future development prospects,” said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide. “The Series C/C+ financing is a significant milestone for HighTide. It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations.”
About HighTide Therapeutics HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The U.S. Food and Drug Administration (FDA) granted Fast Track designation to HTD1801 for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program. For more information, please visit www.hightidetx.com.
Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
Dr. Vankayalapati said of the data, “We are excited to have found a way to promote degradation in neuroendocrine prostate cancer cells and hope that this will lead to the first targeted treatment for those who are not responders to current treatment, particularly mCRPC.”
Poster Title: Orally available, CDK9 Selective, Small Molecule Inhibitor that shows promise in N-MYC-Driven Neuroendocrine Prostate Cancers (NEPC) Session Title: Late-Breaking Research: Molecular/Cellular Biology and Genetics 2 Abstract Number: 8097
About Biolexis Therapeutics Inc. Screening each FIELDS™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process.
Our empirically rich FIELDS™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.
Biolexis was founded by Dr. Hari Vankayalapati and Dr. David J. Bearss, both experienced pharmaceutical entrepreneurs whose combined careers include 9 companies founded, 17 compounds that have entered clinical trials, 150+ publications and 100+ patents issued or pending. Our focus is on the development of FIELDS™ for the purpose of both licensing the technology to external parties and continuing to develop its internal portfolio of products.
Biolexis Therapeutics Inc. Kyle Medley 385-286-1282 biolexistx.com
Contact
